Claims
- 1. A compound of the formula ##STR35## wherein each of R, R.sup.1, R.sup.2 and R.sup.3 are individually H or (C.sub.1 -C.sub.3) alkyl, R.sup.1 can additionally be benzyl or benzoyl when R.sup.2 is (C.sub.1 -C.sub.3) alkyl, and when taken together with the nitrogen to which they are attached, R.sup.1 and R.sup.2 represent a saturated 5-7 membered heterocyclic ring containing permissibly a second hetero atom selected from the group consisting of O and N; except that only one of R.sup.1 and R.sup.2 can be H when Z is CH.sub.2 ;
- Z is O, S or CH.sub.2 ;
- X is S or O;
- n is 2 or 3 when Z is O or S and n is 1, 2 or 3 when Z is CH.sub.2 ;
- R.sup.5 is H or CH.sub.3 ;
- m is 1, 2 or 3;
- A is (C.sub.1 -C.sub.5) alkylene or (CH.sub.2).sub.q X(CH.sub.2).sub.p wherein q and p are individually 0, 1, 2 or 3 and the sum of q plus p is 0-4, and
- B is H, CH.sub.3, (C.sub.3 -C.sub.6)cycloalkyl, naphthyl, pyridyl, (C.sub.1 -C.sub.3)alkylpyridyl, di(C.sub.1 -C.sub.3)alkylpyridyl, hydroxypyridyl, (C.sub.1 -C.sub.3)alkyloxypyridyl, 5-(1,3-benzodioxolyl), 6-(2,3-dihydro-1,4-benzodioxinyl), phenyl permissibly substituted with methylenedioxy or 1 or 2 (same or different) (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkyloxy, halo, OH, benzyloxy, CF.sub.3, (C.sub.1 -C.sub.3)alkyl-O-(C.sub.1 -C.sub.3)alkylene, phenoxy or di[(C.sub.1 -C.sub.3)alkyl]amino(C.sub.1 -C.sub.3)alkylene groups; and pharmaceutically-acceptable acid-addition salts thereof.
- 2. A compound of the formula ##STR36## wherein R, R.sup.1, R.sup.2 and R.sup.3 are H or (C.sub.1 -C.sub.3)alkyl, R.sup.1 is benzyl when R.sup.2 is (C.sub.1 -C.sub.3)alkyl, m is 1-3, A.sup.1 is (C.sub.1 -C.sub.5)alkylene and B.sup.1 is pyridyl, phenyl, 5-(1,3-benzodioxolyl), 6-(2,3-dihydro-1,4-benzodioxinyl), (C.sub.1 -C.sub.3)alkylpyridyl, di(C.sub.1 -C.sub.3)alkylpyridyl, hydroxypyridyl or (C.sub.1 -C.sub.3)alkyloxypyridyl.
- 3. A thiazole derivative as claimed in claim 1 wherein R.sup.1 and R.sup.2 individually represent H or (C.sub.1 -C.sub.3)alkyl, R.sup.1 may additionally represent benzyl when R.sup.2 is (C.sub.1 -C.sub.3)alkyl or R.sup.1 and R.sup.2 taken together with the adjacent nitrogen atom represent a piperidino, pyrrolidino or morpholino group, provided that only one of R.sup.1 and R.sup.2 can be hydrogen when Z is CH.sub.2 ; R.sup.3 is hydrogen or (C.sub.1 -C.sub.3)alkyl; R.sup.5 is hydrogen or methyl; A is (C.sub.1 -C.sub.5)alkylene, B is pyridyl permissibly substituted with OH, (C.sub.1 -C.sub.3)alkyloxy or one or two (C.sub.1 -C.sub.3)alkyl groups; and pharmaceutically-acceptable, acid-addition salts thereof.
- 4. A thiazole derivative as claimed in claim 1, wherein Z is sulfur.
- 5. A thiazole derivative as claimed in claim 1, wherein n is 2.
- 6. A thiazole derivative as claimed in claim 1, wherein R.sup.3 is hydrogen.
- 7. A thiazole derivative as claimed in claim 1, wherein R.sup.5 is hydrogen.
- 8. A thiazole derivative as claimed in claim 1, wherein m is 1.
- 9. A thiazole derivative as claimed in claim 1, wherein R.sup.1 and R.sup.2 are methyl.
- 10. A thiazole derivative as claimed in claim 8, wherein the --(CHR.sup.5).sub.m NR.sup.1 R.sup.2 group is dimethylaminomethyl.
- 11. A thiazole derivative as claimed in claim 1, wherein A is CH.sub.2.
- 12. A thiazole derivative as claimed in claim 1, wherein B is pyridyl, hydroxypyridyl, (C.sub.1 -C.sub.3)alkyloxypyridyl, (C.sub.1 -C.sub.3)alkylpyridyl or di(C.sub.1 -C.sub.3)alkylpyridyl.
- 13. A compound according to claim 12 in which B is pyridyl.
- 14. A thiazole derivative as claimed in claim 12, wherein R is H.
- 15. A compound according to claim 1 in which R, R.sup.3 and R.sup.5 are H, R.sup.1 and R.sup.2 are independently H or (C.sub.1 -C.sub.3)alkyl, X is O, n is 2 or 3, A is methylene and B is pyridyl or pyridyl substituted with 1 or 2 members of the group OH, (C.sub.1 -C.sub.3)alkyl or (C.sub.1 -C.sub.3)alkyloxy.
- 16. A compound according to claim 2 in which B.sup.1 is 3-pyridyl, hydroxy-substituted 3-pyridyl, methyl-substituted 3-pyridyl or dimethyl-substituted 3-pyridyl.
- 17. A compound according to claim 1 in which R.sup.1 is H or methyl and R.sup.2 is methyl.
- 18. A compound according to claim 1 in which the hetero ring formed by R.sup.1, R.sup.2 and the nitrogen to which they are attached is piperidino, pyrrolidino or morpholino.
- 19. A compound according to claim 1, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(3-pyridyl)methyl-4-pyrimidone.
- 20. A compound according to claim 1, said compound being 2-[2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino)-5-[5-(1,3-benzodioxolyl)]methyl-4-pyrimidone.
- 21. A compound according to claim 1, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(6-methyl-3-pyridyl)methyl-4-pyrimidone.
- 22. A compound according to claim 1, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(4-pyridylmethyl)-4-pyrimidone.
- 23. A compound according to claim 1, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-pyridyl)methyl-4-pyrimidone.
- 24. A compound according to claim 1, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-methoxy-4-pyridyl)methyl-4-pyrimidone.
- 25. A compound according to claim 1 said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(5,6-dimethyl-3-pyridyl)methyl-4-pyrimidone.
- 26. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect comprising, per dosage unit, an antisecretorially-effective amount of a compound of claim 1 plus one or more pharmaceutical excipients.
- 27. A pharmaceutical formulation according to claim 26 containing from 10-360 mg. of active drug per dosage unit.
- 28. A pharmaceutical formulation according to claim 26 in which the active antisecretory drug is 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(3-pyridyl)methyl-4-pyrimidone.
- 29. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect comprising, per dosage unit, an antisecretorially-effective amount of a compound according to claim 2 plus one or more pharmaceutical excipients.
- 30. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal whose gastric acid secretion is excessive and who is in need of treatment an antisecretorially-effective amount of a compound according to claim 1.
- 31. A method according to claim 30 in which from 40-360 mg. of drug per day are administered orally to humans.
- 32. A method according to claim 30 in which the oral daily dose is from 0.5-4.8 mg./kg. of mammalian body weight.
- 33. A method according to claim 30 in which 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino)-5-(3-pyridyl)methyl-4-pyrimidone is the antisecretorially effective drug.
- 34. A method according to claim 30 in which 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-methoxy-4-pyridyl)methyl-4-pyrimidone is the antisecretorially effective drug.
- 35. A method according to claim 30 in which 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(4-pyridyl)methyl-4-pyrimidone is the antisecretorially effective drug.
- 36. A method according to claim 30 in which 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-pyridyl)methyl-4-pyrimidone is the antisecretorially effective drug.
- 37. A method according to claim 30 in which 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(6-methyl-3-pyridyl)methyl-4-pyrimidone is the antisecretorially-effective drug.
- 38. A method according to claim 30 in which 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(5,6-dimethyl-3-pyridyl)methyl-4-pyrimidone is the antisecretorially-effective drug.
- 39. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal whose gastric acid secretion is excessive and who is in need of treatment an antisecretorially-effective amount of a compound according to claim 2.
- 40. A method of inhibiting H-2 histamine receptors which comprises administering to an animal an amount effective to inhibit said receptors of a compound according to claim 1.
- 41. A compound of the formula ##STR37## wherein each of R, R.sup.1, R.sup.2 and R.sup.3 are individually H or (C.sub.1 -C.sub.3) alkyl, R.sup.1 can additionally be benzyl or benzoyl when R.sup.2 is (C.sub.1 -C.sub.3) alkyl, and when taken together with the nitrogen to which they are attached, R.sup.1 and R.sup.2 represent a saturated 5-7 membered heterocyclic ring containing permissibly a second hetero atom selected from the group consisting of O and N; except that only one of R.sup.1 and R.sup.2 can be H when Z is CH.sub.2 ;
- Z is O, S or CH.sub.2 ;
- X is S or O;
- n is 2 or 3 when Z is O or S and n is 1, 2 or 3 when Z is CH.sub.2 ;
- R.sup.5 is H or CH.sub.3 ;
- m is 1, 2 or 3;
- A is (C.sub.1 -C.sub.5) alkylene or (CH.sub.2).sub.q X(CH.sub.2).sub.p wherein q and p are individually 0, 1, 2 or 3 and the sum of q plus p is 0-4, and
- B is H, CH.sub.3, (C.sub.3 -C.sub.6)cycloalkyl, naphthyl, pyridyl, (C.sub.1 -C.sub.3)alkylpyridyl, di(C.sub.1 -C.sub.3)alkylpyridyl, hydroxypyridyl, (C.sub.1 -C.sub.3)alkyloxypyridyl, imidazolyl, furyl, thienyl, thiazolyl, tetrahydrofuryl, 5-(1,3-benzodioxolyl), 6-(2,3-dihydro-1,4-benzodioxinyl), phenyl permissibly substituted with methylenedioxy or 1 or 2 (same or different) (C.sub.1 -C.sub.3)alkyl, (C.sub.1 -C.sub.3)alkyloxy, halo, OH, benzyloxy, CF.sub.3, (C.sub.1 -C.sub.3)alkyl-O-(C.sub.1 -C.sub.3)alkylene, phenoxy or di[(C.sub.1 -C.sub.3)alkyl]amino(C.sub.1 -C.sub.3)alkylene groups; and pharmaceutically-acceptable acid-addition salts thereof.
- 42. A compound of the formula ##STR38## wherein R, R.sup.1, R.sup.2 and R.sup.3 are H or (C.sub.1 -C.sub.3)alkyl, R.sup.1 is benzyl when R.sup.2 is (C.sub.1 -C.sub.3)alkyl, m is 1-3, A.sup.1 is (C.sub.1 -C.sub.5)alkylene and B.sup.1 is furyl, thienyl, imidazolyl, thiazolyl or tetrahydrofuryl.
- 43. A compound according to claim 42 in which R and R.sup.3 are H, R and R.sup.2 are methyl, A.sup.1 is methylene and B.sup.1 is thiazolyl, furyl, thienyl, imidazolyl or tetrahydrofuryl.
- 44. A compound according to claim 41, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(4-imidazolyl)methyl-4-pyrimidone.
- 45. A compound according to claim 41, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-furyl)methyl-4-pyrimidone.
- 46. A compound according to claim 41 said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-thiazolyl)methyl-4-pyrimidone.
- 47. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect comprising, per dosage unit, an antisecretorially-effective amount of a compound of claim 41 plus one or more pharmaceutical excipients.
- 48. A pharmaceutical formulation in unit dosage form adapted for oral administration to achieve an antisecretory effect comprising, per dosage unit, an antisecretorially-effective amount of a compound according to claim 42 plus one or more pharmaceutical excipients.
- 49. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal whose gastric acid secretion is excessive and who is in need of treatment an antisecretorially-effective amount of a compound according to claim 41.
- 50. A method for inhibiting gastric acid secretion in mammals which comprises administering to a mammal whose gastric acid secretion is excessive and who is in need of treatment an antisecretorially-effective amount of a compound according to claim 42.
- 51. A method of inhibiting H-2 histamine receptors which comprises administering to a mammal an amount effective to inhibit said receptors of a compound according to claim 41.
- 52. A method of inhibiting H-1 histamine receptors which comprises administering to a mammal an amount effective to inhibit said receptors of a compound according to claim 41.
- 53. A method of inhibiting both H-1 and H-2 receptors which comprises administering to a mammal an amount effective to inhibit said receptors of a compound according to claim 41.
- 54. A compound according to claim 1, said compound being 2-[2-(2-dimethylaminomethyl-4-thiazolylmethylthio)ethyl]amino-5-(2-methyl-4-pyridyl)methyl-4-pyrimidone.
CROSS-REFERENCE
This is a continuation-in-part application of my copending application Ser. No. 334,784, filed Dec. 28, 1981, now abandoned.
Foreign Referenced Citations (1)
Number |
Date |
Country |
83186 |
Jul 1983 |
EPX |
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
334784 |
Dec 1981 |
|